UCB NOVEL DRUG CANDIDATES

Promoteur – Intermédiaire Financier

UCB SA

Lieu

• Belgique
• Royaume-Uni

Description

Financing of UCB New Medicines activities in the fields of neuroscience (Braine-l'Alleud, Belgium) and immunology (Slough, UK) over the period 2015-2017

Objectifs

The project concerns the discovery research, non-clinical developments and early clinical developments, i.e. finding and confirming candidates and progressing them through proof of concept stage in the areas of neurology and immunology.

Commentaires

Professional, Scientific and Technical Activities

Secteur(s)

• Services - Activités spécialisées, scientifiques et techniques

Montant BEI envisagé (montant approximatif)

EUR 150 million

Coût total (montant approximatif)

EUR 426 million

Aspects environnementaux

The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

Passation des marchés

The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having the status of a contracting entity, thus not subject to EU rules on public procurement. However, if, after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2004/17/EC), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2004/17/EC and Directive 92/13/EEC), with publication of tender notices in the EU Official Journal, as and where required.

Statut

Signé - 15/12/2015